Member Info for Aether

Let's not go off on a Vax / Anti-V debate.

For the US market, surely preventing a patient going to hospital would make this very attractive for administration at home.

Tony

Thank you for taking the time to reply.

So, all the benefits you mentioned associated with having a biobank for SPRINTER 3 also applies to ACTIV-2 P2 albeit the profitability of home and hospital setting might be different?

Tornadotony

There's a thread with a question for you over on the SNG board. Thanks.

It will be harder to prove this in a new trial because the symptoms of the new variants are milder.

*bump*

"ACTIV2 has collected blood samples so that too is highly significant."

So, unlike SPRINTER 3, they have a biobank?

Don't feed it.

Bin it.

What are the implications of these findings for SNG?

Ha. Those figures sucked people into this mess.

I think Numis states 220p?

The question is how cheap?

If the deep dive SPRINTER 3, Activ-2 P2, and Long Covid data are good...

Could they buy the company and then sell the IP to a larger pharmaceutical company?

Why are Polygon going over 25%?

Has anyone sent them an email requesting clarification on this?

The writing style is very similar to "Andy".

Green bin the paid shill and its sock puppets.

Green bin it.

Don't feed it.

Gaslighting people now.

Best to green bin.

They're sock puppets.

TommyD

Polygon are MASSIVELY underwater.

How do they extricate themselves quickly and with maximum value?

Buy the company cheaply. (Why go above 25%?)

Delist.

Sell the IP to a larger pharmaceutical company.